Monday, August 17, 2020

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Top Health News -- ScienceDaily https://ift.tt/317NlC5
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists found the “holy grail” gene that could one day help humans regrow limbs

Scientists studying axolotls, zebrafish, and mice have uncovered a shared set of genes that may one day help humans regrow lost limbs. By id...